IPOX 100 U.S. hits home run as MyoKardia (MYOK) surges +60% / ETF: FPX
IPOX Schuster LLC, the firm behind the IPOX Indexes Strategies, is pleased to note the takeover of biotech MyoKardia (MYOK) by Bristol-Myers Squipp (BMY) at a +60% premium. MyoKardia (MYOK) is a constituent of a number of IPOX Indexes, including the IPOX 100 U.S. which currently tracks the performance of $2.7 trillion U.S. dollars tied to 100 of the largest U.S. domiciled IPOs in the United States using the IPOX Indexes Technology.
Between its launch on August 6, 2004 and October 2nd, 2020 and adjusted for dividends, the IPOX 100 U.S. Index (IPXUOTR) has gained +955.82% vs. +339.37% for the S&P 500 (SPXT), benchmark for U.S. stocks.
The IPOX 100 U.S. Index serves as the underlying for a number of available investment products, including the NYSE-traded $1.6 billion First Trust U.S. Equity Opportunities Fund (FPX) (https://bit.ly/3jwG6Kw), an exchange traded fund.
For IPOX 100 U.S. Index factor research, please follow: https://bit.ly/30AQauv
For further information, please contact us using the co-ordinates below. Thank you.
IPOX Schuster LLC
1-312-339-4114 (24.7 support)